Compared with the control group, PSCs treated with Arl4c-overexpressing cancer cell CM (Arl4c-CM) showed a higher expression level of αSMA, as identified using immunofluorescence (IF) staining (Figure 2A). This evidence concerns the gene ACTA1 and cancer.